Search results
Results from the WOW.Com Content Network
Alnylam still does not earn money, but writes losses. The losses ("GAAP Operating Loss") from Alnylam were around $650 million in the late 2020. Alnylam expects to achieve net profits financially in 2022 or 2023. [40] In July 2023, Roche partnered with Alnylam Pharmaceuticals in a deal worth $2.8 billion for the development of a hypertension ...
Shares of Alnylam Pharmaceuticals (NASDAQ: ALNY), a biotech company developing a new class of medications based on RNAi technology, have soared 250% since the start of 2013. Why are investors so ...
Regulus Therapeutics Inc. is a clinical stage biopharmaceutical company focused on the development of first-in-class drugs that target microRNAs to treat a broad range of diseases. Regulus was established in September 2007 by Alnylam Pharmaceuticals and Isis Pharmaceuticals. [1]
About Alnylam Pharmaceuticals. Alnylam is a biopharmaceutical company developing novel therapeutics based on RNA interference, or RNAi. The company is leading the translation of RNAi as a new ...
About Alnylam Pharmaceuticals Alnylam is a biopharmaceutical company developing novel therapeutics based on RNA interference, or RNAi. The company is leading the translation of RNAi as a new class ...
What: Shares of Alnylam Pharmaceuticals , a. Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're ...
The Medicines Company has licensed Alnylam Pharmaceuticals' cholesterol-lowering ALN-PCS RNAi therapeutic program, the companies announced today. Alnylam is due $25 million upfront from The ...
In the case of Alnylam Pharmaceuticals , the sell-side seems so eager to make a bullish case that "Biotechs are risky" is a standard boilerplate warning when writing about the sector, but some ...